Ireland
--:--IST
Starting soon Not applicable

Imaging and Spectral Analysis of the Crystalline Lens Using the "HYPERLAF" Slit Lamp

NCT07875205 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-10
Last updated
2026-10-15

Condition(s) studied

Cataract

Investigational drug(s) / intervention(s)

Non-contact observation of the crystalline lens nucleus

Non-contact observation of the crystalline lens nucleus: Non-contact observation of the crystalline lens nucleus with a modified slit lamp combining an imaging system and a spectral measurement.

Study summary

Cataract is the leading cause of reversible blindness and the first surgery worldwide. It corresponds to the crystalline lens opacification. Nevertheless, its grading remains mostly subjective and the Lens Opacities Classification System dating back 1993, is not used in daily practice and has not been revisited since. The HYPERLAF device developed by the start-up HYPEREYE is a modified slit lamp which combines imaging and spectral analysis, providing two quantitative objective scores: OPAK (opacity) and COLOR (spectral analysis). It is a non-CE marked prototype with non-invasive imaging methods.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : * Patients enrolled in or eligible for a social security program * Age 18 or older * Patients with cataracts. In cases of bilateral cataracts, both eyes will be photographed and analyzed. * Patient who has already received an instillation of 0.5% mydriaticum (tropicamide) and 10% neosynephrine (Théa Laboratories, Clermont-Ferrand, France) eye drops to dilate the pupil of the eye to be photographed (or both eyes). * Signature of the consent form Exclusion Criteria : * Severe blepharospasm making the examination impossible. * Poor or absent pupil dilation: patient with an allergy or intolerance to the eye drops used for pupil dilation; refusal of pupil dilation during the eye examination. * Pregnant or breastfeeding patient * person under legal guardianship

Primary outcome measure(s)

  • Reproducibility of COLOR score measurement. — at inclusion, This is a one-day study.
    To assess the reproducibility of the COLOR score measurement, we will perform three consecutive measurements for each lens in each subject. In practice, the measurement procedure will be repeated from the beginning: for each measurement, the patient will sit on the LAF, the observer will focus the light on the lens, take the measurement, and then move on to the other eye. At the end, the patient will step back. Reproducibility will be quantified using the intraclass correlation coefficient (ICC).

Trial sites (1)

FacilityCityRegionStatus
CHU de Saint-Etienne Saint-Etienne France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07875205 on ClinicalTrials.gov ↗ ← All trials in France